Can I Take Creatine with Wegovy?

What Is Wegovy and Why Does Muscle Loss Matter?

Wegovy is a once-weekly subcutaneous injection of semaglutide 2.4 mg approved by the FDA in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity [1]. In the STEP-1 trial (N=1,961), participants lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo [2].

That weight loss is not purely fat. Analysis of the STEP-1 body-composition substudy showed lean mass accounted for approximately 39% of total weight lost [3]. Losing that much skeletal muscle raises long-term metabolic risk and can reduce strength and function, which is exactly why clinicians increasingly recommend resistance training and protein-sparing supplements alongside GLP-1 therapy.

Why Patients Ask About Creatine

Creatine monohydrate is one of the most studied ergogenic supplements in the world. A 2017 position stand from the International Society of Sports Nutrition concluded that creatine supplementation combined with resistance training increases lean mass and upper- and lower-body strength compared with training alone [4]. For a patient losing weight rapidly on semaglutide, those properties are directly relevant.

The Lean-Mass Problem on GLP-1 Therapy

The concern is not trivial. A 2023 analysis published in Diabetes, Obesity and Metabolism found that patients on semaglutide who did not participate in structured resistance training lost significantly more lean mass per kilogram of total weight lost than those who did [5]. Creatine supports phosphocreatine resynthesis in muscle, sustaining ATP availability during short, high-intensity contractions, which means it works synergistically with the resistance training already recommended for GLP-1 patients [4].

Does Creatine Interact with Wegovy Pharmacokinetically?

No pharmacokinetic interaction between creatine monohydrate and semaglutide 2.4 mg has been identified in the published literature or in the FDA-approved prescribing information for Wegovy [1].

How Semaglutide Is Metabolized

Semaglutide is a GLP-1 receptor agonist. It is metabolized by proteolytic cleavage and beta-oxidation of the fatty acid chain. It does not rely on cytochrome P450 enzymes for clearance [6]. Because creatine is also not a CYP substrate, there is no shared enzymatic pathway that could produce a drug-supplement interaction [7].

How Creatine Is Handled by the Body

Dietary creatine is absorbed in the small intestine and transported to skeletal muscle via the SLC6A8 creatine transporter. Inside muscle cells it is phosphorylated to phosphocreatine. A small, stable fraction (roughly 1 to 2% per day) is non-enzymatically converted to creatinine and excreted by the kidneys [8]. That conversion is the source of the lab-value problem described in the next section.

Gastric Emptying: A Theoretical Note

Semaglutide slows gastric emptying, which can reduce peak absorption of some oral drugs [9]. For creatine, slower gastric transit may reduce the rate of intestinal absorption but is unlikely to reduce the total amount absorbed, because creatine is absorbed passively across the entire small intestinal surface [10]. No clinical study has quantified this effect specifically, but it does not represent a safety concern.

The Creatinine Lab-Value Problem

This is the most clinically important issue. Creatinine is both a waste product of muscle metabolism and the metabolic byproduct of supplemental creatine. When your prescriber orders a basic metabolic panel to monitor kidney function, the assay cannot distinguish between creatinine from muscle breakdown and creatinine from your creatine supplement.

How Much Does Creatine Raise Serum Creatinine?

A double-blind crossover trial (N=18) published in the Journal of the American Society of Nephrology measured serum creatinine before and during creatine supplementation at 5 g/day. Serum creatinine rose by a mean of 0.18 mg/dL, placing some subjects above the upper limit of the normal reference range despite stable glomerular filtration rate confirmed by inulin clearance [11]. A 2003 study in Kidney International found similar results, with creatinine rising approximately 0.1 to 0.2 mg/dL above baseline during maintenance dosing [12].

The loading phase matters. A loading protocol of 20 g/day for five to seven days produces a sharper, faster rise in serum creatinine than maintenance dosing of 3 to 5 g/day [8]. Patients starting creatine with a loading phase during active Wegovy titration are more likely to trigger a reflex nephrology referral or medication hold based on a lab artifact rather than true renal deterioration.

Why This Matters Specifically for Wegovy Patients

The Wegovy prescribing information does not list creatine as a contraindication, but it does note that semaglutide has not been studied in patients with a history of pancreatitis, and clinicians typically order repeated metabolic panels during dose escalation [1]. A creatinine that jumps from 0.9 to 1.1 mg/dL between visits looks like a 22% increase in a marker of kidney injury. Without knowing the patient is taking creatine, that finding can trigger unnecessary dose holds, imaging, or nephrology referrals.

Cystatin C: The Better Kidney Marker

Cystatin C is a kidney filtration marker that is not affected by muscle mass or dietary creatine intake [13]. If you are taking creatine and your prescriber wants to monitor kidney function, requesting a cystatin-C-based eGFR alongside the standard creatinine-based eGFR gives a clearer picture. The 2012 CKD-EPI cystatin C equation has been validated across a broad range of GFR values [14].

Is There Any Pharmacodynamic Interaction?

A pharmacodynamic interaction would mean creatine changes the effect of semaglutide on blood glucose, appetite, or weight, or that semaglutide changes the effect of creatine on muscle or strength. No such interaction has been reported.

Blood Glucose

Creatine may modestly improve glycemic control. A meta-analysis of 22 randomized controlled trials (N=1,317) found that creatine supplementation reduced fasting blood glucose by a mean of 0.27 mmol/L (95% CI: 0.13 to 0.41) and HbA1c by 0.10% [15]. This small glucose-lowering signal could theoretically add to semaglutide's own glucose-lowering effect. For most Wegovy patients using it for weight management without type 2 diabetes, this is not a concern. For patients with type 2 diabetes who are also on insulin or sulfonylureas, a small additive effect on glucose is worth knowing about, though the magnitude is modest.

Appetite and Weight

No evidence suggests creatine meaningfully affects appetite or GLP-1 receptor signaling. Creatine does cause intracellular water retention in muscle cells, typically 0.5 to 1.5 kg of total body water in the first one to two weeks of use [4]. This gain in scale weight is not fat and does not reflect a blunting of Wegovy's action, but it can briefly slow the downward trend on the scale, which may concern patients who are closely tracking their weight loss progress.

What the Evidence Says About Creatine During Caloric Restriction

GLP-1 therapy produces a caloric deficit comparable to a medically supervised very-low-calorie diet. Research in that deficit setting is directly relevant.

Resistance Training Plus Creatine

A 12-week randomized controlled trial published in Medicine and Science in Sports and Exercise (N=36) studied creatine supplementation in older adults during a controlled energy deficit combined with resistance training. The creatine group preserved significantly more lean mass (mean difference: 1.3 kg, P<0.05) and had greater gains in leg press strength than the placebo group [16]. Older adults are the population most likely to suffer clinically meaningful sarcopenia on GLP-1-driven weight loss, so this finding is particularly applicable.

Protein Intake Still Comes First

The 2023 American Society for Metabolic and Bariatric Surgery position paper on nutritional management during GLP-1 therapy recommends a minimum protein intake of 1.2 g/kg of ideal body weight per day to preserve lean mass [17]. Creatine is an adjunct to adequate protein, not a substitute. Patients who hit their protein targets and train with resistance will get more benefit from creatine than sedentary patients taking creatine alone.

Does the Caloric Deficit Affect Creatine Uptake?

Creatine uptake into muscle is driven by the SLC6A8 transporter and is largely independent of total caloric intake. Insulin modestly upregulates transporter expression, so combining creatine with a carbohydrate-containing meal may slightly improve muscle uptake [8]. Taking 5 g of creatine monohydrate with a post-workout meal that includes carbohydrates remains a reasonable practice on Wegovy, even if total daily caloric intake is reduced.

Renal Safety: What the Data Actually Show

The most persistent myth about creatine is that it damages kidneys in healthy people. This has been studied extensively.

Long-Term Data in Healthy Subjects

A three-year longitudinal study in trained athletes supplementing with creatine at 5 to 10 g/day found no change in creatinine clearance, urine albumin, or any other marker of kidney injury compared with non-supplementing controls [18]. A systematic review of 12 studies involving healthy individuals found no evidence of nephrotoxicity at doses up to 10 g/day for durations up to two years [19].

People with Pre-Existing Kidney Disease

The story changes for patients with pre-existing chronic kidney disease (CKD). Current clinical guidance from the National Kidney Foundation advises caution with creatine supplements in patients with CKD stages 3 to 5, because impaired creatinine excretion can cause greater accumulation and more significant elevation of serum creatinine [20]. Wegovy is not specifically contraindicated in mild-to-moderate CKD, but prescribers typically monitor renal function closely in that population. Patients with CKD should discuss creatine use explicitly with their prescribing clinician before starting.

Hydration Matters

Creatine increases intramuscular water retention. Adequate fluid intake (at least 2 to 3 liters of water per day) is standard advice for creatine users and is independently good practice for anyone on a GLP-1 agent, since nausea-related reduced appetite can also reduce fluid intake [4].

Practical Dosing and Monitoring Protocol

The following protocol synthesizes current evidence and applies it to the specific situation of a patient taking Wegovy and beginning creatine supplementation.

Before Starting Creatine

Order or request a baseline comprehensive metabolic panel, including serum creatinine, BUN, and eGFR. If baseline eGFR is below 60 mL/min/1.73 m² (CKD stage 3a or worse), consult your prescribing clinician before starting creatine. Document supplement use in your medical record.

Dosing Strategy

Skip the loading phase. Starting at 3 to 5 g of creatine monohydrate per day without a loading phase keeps the initial creatinine rise gradual and easier to interpret on labs. This approach reaches near-complete muscle saturation in approximately 28 days rather than 5 to 7 days [4]. The slower timeline is a reasonable trade-off for cleaner lab interpretation during Wegovy dose escalation.

Take creatine with a meal that contains carbohydrates and protein. Post-resistance-training timing maximizes uptake, though total daily dose matters more than precise timing [8].

Monitoring After Starting

Recheck serum creatinine and eGFR four to six weeks after starting creatine, and always inform your lab ordering clinician of your supplement use before the blood draw. If cystatin C is available, request it alongside standard creatinine at the first monitoring visit. The eGFR-cystatin C value provides a creatine-independent estimate of kidney filtration [14].

Red Flags That Warrant Stopping

Stop creatine and contact your prescriber if any of the following occur: eGFR drops more than 15 mL/min/1.73 m² from baseline, urine becomes persistently dark or foamy (possible proteinuria), or you develop flank pain. These findings may indicate a true kidney problem, not a lab artifact.

What Wegovy's Prescribing Information Says About Supplements

The FDA-approved labeling for Wegovy does not list creatine or any other ergogenic supplement as a contraindicated concomitant agent [1]. The label does note that semaglutide slows gastric emptying and that this effect may alter the absorption of orally administered drugs, warranting monitoring for oral medications with narrow therapeutic windows [1]. Creatine does not have a narrow therapeutic window, so this warning does not practically apply to creatine supplementation.

The American Association of Clinical Endocrinology 2023 clinical practice guideline on obesity pharmacotherapy states: "Patients prescribed GLP-1 receptor agonists should be counseled on adequate protein intake and resistance exercise to mitigate lean mass loss; adjunctive supplements with an established safety profile may be considered as part of an individualized plan" [21].

Summary of Key Points for Patients and Prescribers

Creatine monohydrate does not interact with semaglutide at a pharmacokinetic level. The main practical issue is the creatinine lab artifact. Telling your prescriber you are taking creatine before any blood draw costs nothing and prevents unnecessary clinical workload.

For most healthy adults on Wegovy, starting creatine at 3 to 5 g/day without a loading phase, combined with consistent resistance training and adequate protein intake, carries a favorable benefit-to-risk profile. Patients with eGFR below 60 mL/min/1.73 m² need individualized guidance before adding creatine.